previous
use
human
parainfluenza
viru
type
vector
express
ebola
viru
ebov
gp
glycoprotein
result
vaccin
immunogen
protect
ebov
challeng
nonhuman
primat
model
howev
remain
unclear
whether
vaccin
would
effect
adult
due
preexist
immun
immunogen
compar
rhesu
monkey
singl
dose
titer
ebovspecif
serum
elisa
neutral
antibodi
substanti
less
anim
compar
anim
howev
two
dose
previous
determin
requir
complet
protect
ebov
challeng
antibodi
titer
indistinguish
two
group
vaccin
viru
appear
replic
reduc
level
respiratori
tract
despit
preexist
immun
may
reflect
known
abil
reinfect
may
also
reflect
presenc
ebov
gp
vector
virion
confer
resist
neutral
vitro
antibodi
data
suggest
immunogen
adult
well
children
ebola
viru
ebov
along
marburg
viru
belong
famili
filovirida
caus
period
outbreak
sever
hemorrhag
fever
high
mortal
central
africa
viru
transmit
direct
contact
infect
person
biolog
fluid
cadav
viru
highli
contagi
transmiss
occur
mucos
surfac
andor
break
skin
review
sanchez
geisbert
feldmann
aerosol
ebov
demonstr
caus
lethal
infect
monkey
johnson
et
al
correspond
author
mail
address
lid
niaid
nih
south
drive
room
bethesda
md
phone
fax
abukreyev
inaidnihgov
publish
disclaim
pdf
file
unedit
manuscript
accept
public
servic
custom
provid
earli
version
manuscript
manuscript
undergo
copyedit
typeset
review
result
proof
publish
final
citabl
form
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
therefor
viru
consid
potenti
agent
biolog
warfar
bioterror
earli
attempt
develop
vaccin
ebov
base
inactiv
viral
particl
purifi
antigen
approach
sometim
protect
rodent
protect
poorli
protect
nonhuman
primat
review
kuhn
recent
vector
vaccin
viruslik
particl
prove
protect
nonhuman
primat
model
jone
et
al
sullivan
et
al
review
bukreyev
collin
human
parainfluenza
viru
type
common
pediatr
respiratori
viru
member
famili
paramyxovirida
envelop
viru
singl
negativesens
strand
genom
rna
nucleotid
liveattenu
pediatr
vaccin
activ
develop
includ
use
vector
express
protect
antigen
pediatr
virus
karron
et
al
thu
substanti
experi
natur
histori
human
administr
deriv
clinic
trial
interest
evalu
potenti
vector
ebov
emerg
pathogen
induc
strong
mucos
respons
addit
strong
system
respons
thu
particularli
effect
protect
mucos
surfac
modifi
express
ebov
glycoprotein
gp
ebov
envelop
surfac
protein
addit
gene
insert
p
gene
bukreyev
et
al
respiratori
tract
immun
guinea
pig
caus
diseas
signific
lung
patholog
evid
viral
spread
beyond
respiratori
tract
evid
patholog
chang
intern
organ
bukreyev
et
al
yang
et
al
similarli
well
wild
type
parent
asymptomat
nonhuman
primat
bukreyev
et
al
lack
virul
deriv
nonhuman
experiment
anim
presum
reflect
host
rang
restrict
human
viru
thu
evalu
vector
base
wild
type
nonhuman
experiment
anim
provid
model
attenu
deriv
human
evid
express
ebov
gp
increas
vector
replic
tropism
vivo
inde
titer
respiratori
tract
guinea
pig
monkey
similar
lower
empti
vector
bukreyev
et
al
yang
et
al
importantli
vaccin
found
protect
intraperiton
challeng
highli
lethal
dose
ebov
guinea
pig
nonhuman
primat
model
infect
bukreyev
et
al
bukreyev
et
al
howev
essenti
adult
human
preexist
immun
natur
exposur
immun
would
expect
restrict
replic
vector
might
drastic
reduc
immunogen
foreign
insert
antigen
therefor
unclear
whether
vector
would
effect
human
inde
preexist
immun
viral
vector
one
base
vaccinia
viru
adenoviru
type
greatli
reduc
immun
respons
express
foreign
antigen
see
discuss
surprisingli
guinea
pig
previous
infect
immun
singl
dose
induc
titer
ebovspecif
serum
antibodi
nearli
equal
detect
anim
yang
et
al
howev
sinc
evalu
vaccin
rodent
model
produc
overli
optimist
result
test
nonhuman
primat
import
step
evalu
immunogen
efficaci
particularli
true
filoviru
vaccin
geisbert
et
al
studi
evalu
immunogen
monkey
found
preexist
immun
reduc
prevent
replic
vaccin
respiratori
tract
level
ebovspecif
antibodi
equal
primat
follow
two
dose
vaccin
compar
immunogen
nonimmun
anim
infect
monkey
two
dose
four
week
apart
combin
intranas
intratrach
rout
dose
contain
tissu
cultur
infecti
dose
tcid
per
site
fig
first
dose
induc
hemagglutin
inhibit
hai
serum
antibodi
geometr
mean
titer
increas
second
dose
fig
essenti
human
infect
infanc
earli
childhood
may
reinfect
thereaft
thu
typic
adult
infect
henc
anim
receiv
two
dose
case
infect
recent
substanti
compon
protect
cellular
immun
induc
infect
lost
within
month
tao
et
al
thu
lost
typic
adult
order
model
situat
anim
rest
month
second
dose
detect
reduct
level
serum
antibodi
time
fig
thereaft
two
monkey
ad
studi
control
six
anim
immun
two
dose
week
apart
combin
rout
plaqueform
unit
pfu
per
site
fig
use
higher
dose
appear
attenu
vivo
compar
exampl
replic
less
effici
lung
guinea
pig
previou
studi
yang
et
al
differ
appar
earlier
studi
monitor
shed
rhesu
monkey
bukreyev
et
al
howev
rhesu
monkey
dose
tcid
per
site
induc
serum
antibodi
respons
augment
second
dose
thu
appear
maxim
note
wherea
previou
studi
rhesu
monkey
dose
tcid
per
site
induc
higher
serum
antibodi
respons
vector
insert
dose
tcid
per
site
bukreyev
suggest
higher
dose
would
necessari
approach
maxim
respons
previous
demonstr
two
dose
requir
uniform
protect
ebov
challeng
nonhuman
primat
model
bukreyev
et
al
consist
studi
administr
first
dose
anim
present
studi
induc
substanti
titer
serum
ebovspecif
igg
iga
quantifi
enzymelink
immunosorb
assay
elisa
fig
c
second
dose
follow
modest
increas
antibodi
titer
although
day
second
dose
titer
serum
igg
iga
diminish
induc
first
dose
fig
c
titer
ebovneutr
antibodi
assay
abil
neutralizeth
viru
garbutt
et
al
recombin
version
vesicular
stomat
viru
vsv
vsv
envelop
glycoprotein
g
delet
replac
ebov
gp
sole
viral
surfac
protein
chimer
viru
depend
ebov
gp
cell
attach
entri
therefor
suitabl
altern
neutral
assay
toth
authent
ebov
zair
viru
requir
biosafeti
level
bsl
facil
anim
immun
detect
geometr
mean
titer
ebovneutr
antibodi
first
dose
increas
second
dose
fig
monkey
first
dose
induc
titer
ebovspecif
serum
igg
iga
antibodi
significantli
reduc
compar
monkey
fig
c
howev
follow
second
dose
titer
serum
igg
iga
anim
essenti
equal
anim
ebovneutr
antibodi
detect
first
dose
howev
second
dose
geometr
mean
titer
detect
exceed
titer
group
fig
data
indic
two
dose
immunogen
monkey
monkey
also
perform
neutral
assay
sera
two
two
anim
absenc
guinea
pig
complement
interestingli
littl
ebovneutr
activ
detect
sampl
particular
low
titer
detect
sera
one
one
monkey
respect
second
first
dose
data
shown
data
suggest
least
case
vaccin
complement
system
import
compon
ebov
neutral
antibodi
experi
shown
fig
nasal
swab
ns
tracheal
lavag
tl
collect
immun
immun
anim
fig
order
measur
vaccin
viru
shed
sampl
assay
plaqu
titrat
titer
express
pfuml
ns
tl
fluid
rel
high
titer
viabl
vaccin
viruswer
detect
ns
tl
specimen
collect
monkey
day
day
first
dose
vaccin
fig
contrast
infecti
viru
detect
ns
tl
specimen
collect
monkey
furthermor
infecti
viru
detect
ns
tl
specimen
either
group
collect
second
dose
vaccin
data
suggest
immun
induc
strongli
restrict
replic
subsequ
dose
ebogp
howev
previous
show
uvinactiv
induc
low
level
ebovspecif
serum
antibodi
guinea
pig
model
indic
signific
immun
respons
depend
replic
yang
et
al
note
later
report
uvinactiv
also
induc
detect
igg
iga
elisa
serum
antibodi
rhesu
monkey
show
replic
necessari
signific
immunogen
nonhuman
primat
thu
increas
immun
respons
dose
monkey
present
studi
rais
possibl
replic
occur
follow
dose
even
though
infecti
viru
detect
ns
tl
specimen
plaqu
assay
therefor
use
quantit
revers
transcript
polymeras
chain
reaction
rtpcr
quantifi
rna
present
ns
tl
specimen
monkey
control
analysi
specimen
two
monkey
infect
unrel
viral
vector
ie
sampl
collect
day
inocul
rhesu
monkey
pfu
recombin
newcastl
diseas
viru
express
ebov
gp
jmd
plc
ab
unpublish
data
indic
nonspecif
background
log
pfu
equivalentsml
ns
tl
respect
first
dose
anim
level
viral
rna
significantli
exceed
nonspecif
control
ns
tl
time
point
importantli
substanti
concentr
viral
rna
also
detect
mani
ns
tl
specimen
monkey
mostli
day
fig
interestingli
second
dose
ebogp
high
concentr
rna
detect
ns
specimen
anim
wherea
littl
rna
detect
tl
specimen
fig
data
indic
rna
vector
present
respiratori
tract
monkey
first
dose
also
second
dose
next
ask
whether
vector
rna
detect
respiratori
tract
secret
repres
progeni
viru
produc
viral
replic
vivo
repres
initi
viral
inoculum
distinguish
two
possibl
perform
separ
experi
four
seroneg
rhesu
monkey
two
monkey
inocul
live
two
uvinactiv
anim
receiv
either
viru
combin
rout
pfu
equival
per
site
day
ns
tl
collect
analyz
presenc
viabl
viru
plaqu
titrat
fig
presenc
rna
quantit
rtpcr
fig
expect
plaqu
assay
ns
tl
specimen
collect
two
monkey
receiv
live
viru
reveal
viral
titer
compar
observ
first
monkey
experi
shown
fig
wherea
infecti
viru
detect
specimen
two
anim
receiv
uvinactiv
fig
furthermor
quantit
rtpcr
demonstr
presenc
rna
ns
tl
sampl
monkey
inocul
live
concentr
compar
observ
first
monkey
experi
shown
fig
sampl
collect
monkey
inocul
uvinactiv
fig
control
compar
sensit
quantit
rtpcr
live
versu
uvinactiv
found
uv
inactiv
reduc
sensit
assay
log
shown
loss
sensit
presum
due
damag
rna
templat
introduct
uracil
dimer
sinc
even
uv
dose
minim
requir
complet
inactiv
viru
use
larg
fraction
rna
molecul
receiv
multipl
hit
event
valu
well
differ
level
rna
ns
tl
sampl
posit
viral
rna
limit
detect
exampl
differ
level
rna
detect
monkey
day
limit
detect
log
log
ns
tl
respect
fig
indic
vector
rna
detect
ns
tl
specimen
follow
first
second
inocul
due
replic
viru
rather
residu
inoculum
final
collect
serum
sampl
day
follow
immun
uvinactiv
versu
infecti
uvinactiv
viru
induc
detect
ebovspecif
elisa
igg
iga
serum
antibodi
wherea
strong
respons
observ
anim
receiv
infecti
similar
result
describ
previou
work
shown
confirm
replic
necessari
signific
ebovspecif
antibodi
respons
primat
previous
observ
guinea
pig
yang
et
al
next
attempt
determin
vaccin
viru
detect
respiratori
secret
quantit
rtpcr
plaqu
titrat
one
possibl
inde
secret
respiratori
tract
epitheli
cell
neutral
antibodi
present
respiratori
tract
either
immedi
upon
releas
vitro
analysi
specimen
plaqu
assay
investig
possibl
perform
spike
experi
vitro
replic
aliquot
contain
pfu
either
mix
ns
tl
specimen
immun
anim
indic
fig
control
test
one
set
specimen
number
fig
collect
day
infect
newcastl
diseas
viru
unpublish
studi
neutral
antibodi
would
expect
present
also
assay
two
set
specimen
number
collect
monkey
day
infect
first
dose
day
earli
time
point
neutral
activ
present
serum
respiratori
tract
secret
would
due
antibodi
present
infect
ie
present
origin
infect
month
earlier
sampl
includ
four
set
specimen
number
collect
anim
day
first
dose
ns
tl
specimen
uvirradi
destroy
infecti
confirm
plaqu
assay
mixtur
incub
h
residu
titer
spike
viru
quantifi
plaqu
titrat
fig
found
consist
reduct
viral
titer
ns
specimen
collect
monkey
contrast
number
pfu
reduc
four
ns
sampl
monkey
least
limit
detect
ns
number
ebogp
reduc
two
four
ns
samplesbi
tl
specimen
collect
monkey
margin
reduc
titer
virus
howev
reduct
much
greater
case
tl
specimen
collect
anim
particular
titer
reduc
least
limit
detect
tl
number
slightli
reduc
reduc
undetect
level
ie
least
tl
number
seemingli
greater
resist
neutral
ns
tl
specimen
would
consist
previou
find
less
suscept
empti
vector
neutral
antibodi
due
presenc
function
ebov
gp
incorpor
vector
particl
bukreyev
et
al
although
number
monkey
examin
insuffici
unequivoc
demonstr
effect
also
test
respiratori
tract
secret
abil
neutral
ad
human
respiratori
syncyti
viru
serolog
unrel
paramyxoviru
found
lack
signific
neutral
activ
shown
support
idea
neutral
activ
specif
data
indic
antibodi
present
ns
tl
specimen
neutral
thu
viru
shed
present
respiratori
secret
monkey
might
miss
plaqu
titrat
report
demonstr
vaccin
ebov
replic
immunogen
nonhuman
primat
inde
level
ebovspecif
serum
antibodi
detect
elisa
import
correl
protect
ebov
review
sullivan
et
al
neutral
assay
follow
two
dose
vaccin
indistinguish
anim
result
contrast
similar
studi
involv
vaccin
two
even
three
dose
vector
base
common
human
viral
pathogen
vaccinia
viru
adenoviru
type
administ
intramuscular
rout
exampl
follow
immun
rhesu
monkey
vaccinia
virusvector
vaccin
express
simian
immunodefici
viru
group
antigen
gag
protein
gagspecif
cytotox
cell
ctl
respons
sever
attenu
preexist
immun
vaccinia
viru
vector
sharp
et
al
clinic
trial
vaccinia
virusvector
vaccin
japanes
enceph
viru
induc
neutral
serum
antibodi
respons
vaccine
prior
immun
vaccinia
viru
kanesathasan
et
al
similarli
preexposur
mice
rhesu
monkey
human
adenoviru
type
serotyp
common
human
popul
sever
attenu
immun
respons
gag
protein
human
immunodefici
viru
type
simian
immunodefici
viru
express
vaccin
base
vector
barouch
et
al
casimiro
et
al
lemckert
et
al
mccoy
et
al
similarli
preexposur
mice
human
adenoviru
type
greatli
reduc
ebovspecif
antibodi
cellmedi
respons
adenoviru
vector
express
ebov
gp
yang
et
al
yang
et
al
nonhuman
primat
present
studi
indic
immunogen
depend
replic
therefor
observ
immunogen
anim
follow
two
dose
suggest
least
replic
occur
follow
dose
despit
preexist
immun
inde
quantit
rtpcr
demonstr
presenc
rna
ns
tl
specimen
anim
follow
dose
data
consist
recent
publish
studi
boukhvalova
princ
blanco
cotton
rat
respiratori
syncyti
viru
rsv
like
respiratori
paramyxoviru
abil
caus
reinfect
review
collin
crow
studi
demonstr
cotton
rat
previous
infect
rsv
second
rsv
infect
result
detect
pfu
lung
evalu
plaqu
assay
homogen
harvest
lung
howev
quantit
rtpcr
analysi
lung
tissu
demonstr
substanti
titer
viral
rna
earli
time
point
compar
primari
infect
author
interpret
data
suggest
preexist
rsv
immun
led
abort
replic
respiratori
tract
tissu
infect
anim
howev
address
altern
possibl
second
infect
might
lead
product
progeni
viru
subsequ
neutral
endogen
antibodi
either
vivo
context
vitro
plaqu
assay
studi
analyz
respiratori
secret
rather
lung
tissu
show
ns
tl
specimen
anim
anim
neutral
ad
vitro
indic
presenc
neutral
antibodi
presenc
virusspecif
antibodi
mucos
secret
infect
respiratori
virus
well
known
brown
et
al
burlington
et
al
suggest
progeni
produc
shed
respiratori
tract
neutral
antibodi
present
respiratori
secret
offer
caveat
demonstr
viral
rna
present
ns
tl
sampl
form
viru
particl
abl
replic
respiratori
tract
presenc
preexist
immun
one
explan
may
lie
abil
respiratori
paramyxovirus
includ
rsv
reinfect
throughout
life
despit
presenc
immun
due
prior
infect
appear
due
sever
factor
exampl
rise
virusspecif
secretori
iga
titer
respiratori
tract
occur
follow
infect
diminish
within
month
virusspecif
serum
antibodi
respons
longerliv
antibodi
gain
access
respiratori
lumen
ineffici
limit
abil
restrict
viru
replic
lumin
epitheli
cell
virusspecif
ctl
induc
infect
diminish
within
month
secondari
respons
may
fast
enough
prevent
extens
viru
replic
furthermor
number
laboratori
present
evid
virusspecif
ctl
function
downregul
respiratori
tract
presum
mean
limit
abil
damag
tissu
claassen
et
al
dinapoli
et
al
fulton
olson
varga
gray
et
al
vallbracht
unsold
ehl
taken
togeth
factor
limit
abil
preexist
immun
restrict
reinfect
respiratori
virus
review
collin
crow
karron
collin
agreement
abovenot
suppress
effect
preexist
antibodi
human
vaccin
ebov
deliv
intramuscularli
bypass
intranas
deliveri
vaccin
least
mice
croyl
et
al
result
report
nonhuman
primat
far
anoth
explan
may
relat
rel
high
pfu
dose
vaccin
viru
might
fulli
neutral
amount
antibodi
avail
local
respiratori
tract
third
explan
may
lie
presenc
function
ebov
gp
envelop
alreadi
note
ebov
gp
incorpor
viral
particl
confer
abil
evad
effici
neutral
antibodi
vitro
bukreyev
et
al
thu
ebov
gp
may
mediat
viru
attach
entri
respiratori
tract
nonhuman
primat
therebi
circumv
neutral
antibodi
respons
limit
level
replic
induc
immun
respons
anim
attain
level
observ
anim
sever
studi
mice
inocul
respiratori
virus
rout
demonstr
migrat
activ
dendrit
cell
lung
drain
lymph
node
occur
within
hour
post
infect
particular
infect
mice
sendai
viru
murin
paramyxoviru
close
relat
lung
dendrit
cell
detect
peribronchi
lymph
node
h
post
infect
grayson
et
al
respiratori
syncyti
viru
rsv
infect
mice
result
accumul
lung
dendrit
cell
mediastin
lymph
node
h
earliest
time
point
test
reach
peak
h
post
infect
luken
et
al
infect
mice
influenza
viru
accumul
lung
dendrit
cell
peribronchi
lymph
node
detect
earli
h
reach
maximum
h
post
infect
moreov
h
follow
infect
mice
pulmonari
dendrit
cell
becam
refractori
activ
secondari
infect
unrel
strain
viru
legg
bracial
data
suggest
activ
respiratori
dendrit
cell
result
migrat
secondari
lymphoid
tissu
primarili
earli
event
viru
infect
appear
mediat
mostli
earli
viral
progeni
produc
limit
number
infect
cycl
rather
viru
produc
later
peak
viral
replic
regard
noteworthi
detect
rna
follow
inocul
anim
greatest
day
postimmun
detect
subsequ
declin
increas
time
earli
time
amount
vector
rna
similar
anim
ns
specimen
somewhat
reduc
tl
specimen
anim
thu
three
featur
vaccin
may
contribut
immunogen
vectorimmun
anim
first
ineffici
preexist
immun
restrict
replic
second
presenc
function
ebov
gp
third
disproportion
role
earli
activ
respiratori
antigenpres
cell
adapt
respons
note
measur
ebovspecif
cellmedi
respons
particular
studi
cellmedi
respons
describ
requir
protect
monkey
ebov
challeng
vaccin
adenoviru
type
vaccin
sullivan
et
al
although
detail
studi
yet
publish
howev
previous
show
administr
respiratori
tract
nonhuman
primat
result
low
sporad
cellular
respons
detect
peripher
blood
might
consequ
cellular
respons
accumul
respiratori
tract
site
infect
review
bukreyev
collin
thu
monitor
cellmedi
respons
present
studi
contrast
serum
antibodi
respons
robust
whether
measur
elisa
neutral
assay
like
play
import
role
protect
review
bukreyev
collin
furthermor
test
protect
efficaci
vaccin
anim
present
studi
due
current
unavail
facil
import
experi
perform
followup
studi
although
note
level
serum
elisa
neutral
antibodi
observ
present
studi
would
consist
high
level
protect
also
note
combin
rout
inocul
use
nonhuman
primat
studi
effort
achiev
uniform
infect
anim
essenti
studi
involv
small
number
anim
deliveri
would
feasibl
human
deliveri
rout
alon
suffici
sinc
human
natur
host
vector
permiss
nonhuman
primat
altern
vaccin
deliv
form
aerosol
use
nebul
mode
deliveri
previous
use
success
deliv
measl
viru
vaccin
four
million
children
fernandez
bracho
roldan
fernandez
fernandezd
castro
et
al
similar
apparatu
recent
use
evalu
vector
respiratori
tract
vaccin
highli
pathogen
avian
influenza
viru
monkey
dinapoli
et
al
present
data
suggest
effect
vector
may
strongli
suppress
preexist
immun
vector
also
develop
altern
strategi
circumv
moder
suppress
immunogen
preexist
immun
vector
specif
develop
construct
ebogp
f
hn
gene
encod
neutral
major
protect
antigen
replac
ebov
gp
insensit
antibodi
vitro
highli
attenu
guinea
pig
strongli
immunogen
anim
complet
protect
ebov
challeng
either
type
vaccin
viru
candid
clinic
trial
adult
bothth
vaccin
sever
import
advantag
first
replic
beyond
respiratori
tract
therefor
safe
second
induc
system
also
local
immun
respons
respiratori
tract
possibl
port
entri
ebov
third
needlefre
increas
safeti
eas
administr
rout
like
effect
combin
rout
test
present
studi
due
full
permiss
human
vector
fourth
product
would
rel
straightforward
sinc
vaccin
repres
replicationcompet
virus
capabl
effect
replic
cell
line
approv
vaccin
product
vero
requir
enhanc
safeti
contain
rhesu
monkey
macaca
mulatta
morgan
island
sc
weigh
kg
prior
use
anim
determin
hai
assay
reciproc
hai
titer
two
studi
perform
first
studi
fig
infect
four
monkey
two
dose
four
week
apart
combin
rout
tcud
per
site
previous
describ
bukreyev
et
al
eleven
month
second
dose
two
addit
monkey
introduc
studi
six
anim
inocul
vaccin
combin
rout
pfu
per
site
four
week
later
second
dose
vaccin
administ
ident
first
dose
ns
tl
collect
day
first
second
dose
vaccin
previous
describ
bukreyev
et
al
second
studi
fig
immun
two
monkey
singl
dose
two
addit
monkey
singl
dose
uvinactiv
ebogpimmun
wereperform
combin
routewith
dose
pfu
inactiv
equival
per
site
ns
tl
sampl
collect
first
experi
perform
bioqual
inc
rockvil
md
second
niaid
facil
poolesvil
md
sitesar
approv
associ
assess
accredit
laboratori
care
intern
procedur
perform
accord
protocol
guidelin
approv
niaid
anim
care
use
committe
bukreyev
et
al
propag
monkey
kidney
cell
chimer
vsvbase
viru
garbutt
et
al
vsv
envelop
protein
g
replac
gp
ebov
kindli
provid
dr
heinz
feldmann
laboratori
virolog
rocki
mountain
laboratori
niaid
nih
propag
titrat
vero
cell
uvinactiv
perform
uv
stratalink
stratagen
la
jolla
ca
use
uv
dose
mjoul
determin
minim
dose
requir
forcomplet
inactiv
infect
prepar
titer
determin
plaqu
titrat
cell
visual
immunostain
previous
describ
bukreyev
et
al
titer
determin
limit
dilut
cell
express
tcid
ml
analysi
quantit
rtpcr
total
rna
isol
cell
cultur
medium
ns
tl
specimen
use
rneasi
mini
kit
qiagen
valencia
ca
accord
manufactur
recommend
rna
subject
revers
transcript
random
hexam
dna
primer
analyz
quantit
pcr
use
primer
specif
nucleoprotein
gene
taqman
gene
express
assay
appli
biosystem
foster
citi
ca
previous
describ
yang
et
al
serum
antibodi
respons
determin
hai
assay
serum
dilut
test
abil
block
agglutin
guinea
pig
erythrocyt
previous
describ
van
wyke
coelingh
winter
murphi
ebovspecif
antibodi
respons
determin
elisa
purifi
gammairradi
ebov
use
antigen
previous
describ
yang
et
al
quantifi
ebovneutr
titer
test
abil
sera
neutral
garbutt
et
al
serial
dilut
heatinactiv
monkey
sera
prepar
optipro
medium
invitrogen
carlsbad
ca
mix
equal
volum
viru
viru
dilutionswer
prepar
tissu
cultur
medium
absenc
presenc
guinea
pig
complement
lonza
inc
allendal
nj
final
concentr
neutral
mixtur
tcid
vv
complement
serumviru
mixtur
incub
h
sampl
equival
tcid
input
viru
ad
confluent
monolay
vero
cell
replic
well
score
viru
replic
visual
determin
cytopath
effect
cpe
h
postinfect
serum
neutral
titer
report
highest
serum
dilut
result
complet
viru
neutral
well
calcul
use
method
reed
muench
reed
muench
statist
signific
calcul
student
test
design
studi
arrow
horizont
line
indic
viru
inocul
indic
day
blood
sampl
collect
day
viru
inocul
blood
sampl
count
first
dose
left
side
first
dose
right
side
horizont
bar
indic
collect
ns
tl
day
immunogen
grey
bar
white
bar
monkey
day
left
side
right
side
b
c
administ
indic
arrow
day
dose
left
side
right
side
b
c
indic
titer
express
reciproc
mean
log
valu
serum
antibodi
ab
level
determin
hai
left
side
antibodi
titer
group
infect
mean
valu
se
four
anim
group
right
side
antibodi
titer
infect
two
anim
mean
valu
four
anim
mean
valu
se
b
c
ebovspecif
serum
igg
b
iga
c
quantit
elisa
use
inactiv
purifi
ebov
antigen
mean
titer
two
mean
titer
se
four
anim
shown
howev
day
bar
indic
x
data
two
anim
augment
analysi
parallel
sampl
three
addit
anim
previou
studi
monkey
immun
exactli
present
studi
bukreyev
et
al
thu
time
point
group
repres
mean
valu
se
total
five
sampl
ebovneutr
neut
serum
antibodi
analyz
use
recombin
vsv
bear
envelop
ebov
gp
sole
viral
surfac
antigen
mean
titer
two
mean
titer
se
four
anim
shown
comparison
igg
iga
respons
panel
b
c
respect
monkey
day
indic
horizont
line
statist
signific
differ
p
indic
asterisk
sampl
antibodi
detect
valu
log
assign
calcul
mean
panel
c
shed
vaccin
viru
monkey
ns
tl
sampl
collect
indic
day
analyz
later
parallel
plaqu
titrat
quantit
rtpcr
bar
repres
individu
monkeya
plaqu
titrat
ns
tl
specimen
dose
limit
detect
pfuml
sampl
viru
detect
valu
twofold
limit
detect
assign
viru
detect
anim
dose
see
result
b
c
quantit
rtpcr
analysi
ns
tl
specimen
dose
b
dose
c
quantit
rtpcr
result
express
pfuml
base
comparison
standard
curv
construct
quantit
rtpcr
analysi
rna
sampl
serial
dilut
prepar
known
pfuml
concentr
nonspecif
background
signal
determin
use
ns
tl
monkey
unpublish
studi
inocul
newcastl
diseas
viru
vector
log
pfu
equivalentsml
ns
tl
respect
assay
repeat
four
time
analysi
ns
tl
specimen
collect
inocul
monkey
uvinactiv
presenc
infecti
viru
plaqu
titrat
presenc
rna
quantit
rtpcr
b
calcul
assay
shown
fig
b
c
bar
repres
individu
monkey
part
limit
detect
pfuml
sampl
viru
detect
valu
twofold
limit
detect
assign
part
b
valu
log
limit
detect
repres
titer
detect
last
least
concentr
dilut
standard
curv
assign
sampl
rna
detect
assay
repeat
two
time
evalu
abil
ns
tl
b
fluid
collect
monkey
neutral
wild
type
viru
black
bar
vaccin
viru
stripe
bar
ad
vitro
pfuml
follow
ns
tl
specimen
control
combin
neutral
test
control
phosphat
buffer
salin
ad
prepar
ns
tl
specimen
collect
day
infect
rhesu
monkey
pfu
newcastl
diseas
viru
previou
unpublish
studi
ns
tl
specimen
collect
two
differ
monkey
collect
day
first
dose
ns
tl
sampl
collect
four
differ
